|
KMID : 0931320090090010011
|
|
대한상부위장관.헬리코박터학회지
2009 Volume.9 No. 1 p.11 ~ p.17
|
|
|
Proton pump inhibitors, Acid secretion, Side effects, Safety
|
|
Park Hye-Won
Jung Hwoon-Yong
|
|
|
Abstract
|
|
|
|
PPIs are being used with increasing frequency to treat acid-related disorders. In general, the tolerability profile of PPIs is good. The most common adverse events of headache, diarrhea, and nausea have been reported in fewer than 5% of patients treated with short-term use of PPIs. Few clinically important interactions have been observed between PPIs and other drugs metabolized by the cytochrome P-450 system. Chronic administration of PPIs may lead enterochromaffin-like cell hyperplasia, but has not been demonstrated to increase the risk of carcinoid formation. Long-term PPIs use has not been documented to hasten the development or the progression of atrophic gastritis and gastric cancer. Bacterial overgrowth and the risk of enteric infection may increase with acid suppression, although this does not seem to be a common clinical problem with prolonged PPIs use. The absorption of fats and minerals does not appear to be significantly impaired with PPIs-induced hypochlorhydria. However, vitamin B12 concentration may be decreased when gastric acid is markedly suppressed for prolonged periods. Taking into account all the available risk/benefit data, PPIs use is strongly justified when clinically indicated. Therefore PPIs should not be used in higher doses or for longer durations than necessary to achieve the desired outcomes.
|
|
|
KEYWORD
|
|
|
Proton pump inhibitors, Acid secretion, Side effects, Safety
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|
|